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Background: In addition to stimulating linear growth in children, growth hormone (GH) influences metabolism and
body composition. These effects should be considered when individualizing GH treatment as dose-dependent
changes in metabolic markers have been reported. Hypothesis: There are different dose-dependent thresholds for
metabolic effects in response to GH treatment.
Method: A randomized, prospective, multicentre trial TRN 98-0198-003 was performed for a 2-year catch-up growth
period, with two treatment regimens (a) individualized GH dose including six different dose groups ranging from
17–100 μg/kg/day (n=87) and (b) fixed GH dose of 43 μg/kg/day (n=41). The individualized GH dose group was
used for finding dose–response effects, where the effective GH dose (ED 50%) required to achieve 50% Δ effect
was calculated with piecewise linear regressions.
Results: Different thresholds for the GH dose were found for the metabolic effects. The GH dose to achieve half of
a given effect (ED 50%, with 90% confidence interval) was calculated as 33(±24.4) μg/kg/day for Δ left ventricular
diastolic diameter (cm), 39(±24.5) μg/kg/day for Δ alkaline phosphatase (μkat/L), 47(±43.5) μg/kg/day for Δ lean soft
tissue (SDS), 48(±35.7) μg/kg/day for Δ insulin (mU/L), 51(±47.6) μg/kg/day for Δ height (SDS), and 57(±52.7) μg/kg/
day for Δ insulin-like growth factor I (IGF-I) SDS. Even though lipolysis was seen in all subjects, there was no
dose–response effect for Δ fat mass (SDS) or Δ leptin ng/ml in the dose range studied. None of the metabolic
effects presented here were related to the dose selection procedure in the trial.
Conclusions: Dose-dependent thresholds were observed for different GH effects, with cardiac tissue being the
most responsive and level of IGF-I the least responsive. The level of insulin was more responsive than that of IGF-I,
with the threshold effect for height in the interval between.
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In addition to stimulating linear growth in children,
growth hormone (GH) influences metabolism and body
composition. For several decades it has been known,
based on results of in vitro and in vivo studies, that GH
has effects on amino acid transport, protein synthesis* Correspondence: Ralph.Decker@vgregion.se
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reproduction in any medium, provided the or[1-3], lipolysis [4,5] and glucose metabolism [2,6,7] after
targeting receptors at different tissues [8]. In addition,
several studies have evaluated metabolic responses to
GH treatment [9-16]. GH replacement therapy in chil-
dren induces favourable changes in metabolic indices
and improves body composition, bone density and re-
modelling, physical and cardiac performance, as well as
overall quality of life [12-17]. If individual responsive-
ness is taken into account, the metabolic response to
GH treatment does not differ markedly between short
children with and without classic GH deficiency (GHD)Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Decker et al. BMC Endocrine Disorders 2012, 12:26 Page 2 of 9
http://www.biomedcentral.com/1472-6823/12/26[18]. The data at baseline has previously been published
[19]. It has been discussed whether any cut-off level of
GH secretion chosen to distinguish between children
with GHD and idiopathic short stature (ISS) may be
arbitrary [19,20].
Dose-dependency with regard to GH has only been
studied in a few clinical trials. It has been shown that GH
treatment increases adult height in a dose-dependent
manner in children with ISS [21]. GH dose-dependency
of metabolic variables has not been clearly defined in
short children owing to a lack of controlled trials on
metabolic outcomes in response to different GH doses.
In a randomized, controlled, clinical trial we have
recently shown that the anabolic and lipolytic effects of
GH can be dissociated in a GH dose range between 17
and 100 μg/kg/day. Anabolism was found to be dose-
dependent while lipolysis was not [18], despite a lipolytic
effect being noted in all subjects. It was interpreted that
the lipolytic effect of GH was overridden in the dose
range used, and that dose-dependency may therefore be-
come apparent at lower doses.
The objective of the present study was to investigate
and compare the GH doses required to achieve different
metabolic responses. The hypothesis was that there are
dose-dependent thresholds for different tissues and
metabolic functions. It was expected that the results
would provide insight into the effective GH dose re-
quired to influence metabolic processes and cardiac tissue
in short children with different GH secretion capacities
and GH responsiveness. The key question was ‘What is
the appropriate GH dose in prepubertal children to com-
pensate for deteriorations in body composition and to
avoid unfavourable metabolic effects?’
Subjects and methods
Ethical consideration
The study protocol (TRN 98-0198-003) was approved by
the Ethics Committees of the Universities of Göteborg
(for Göteborg and Halmstad), Umeå, Uppsala and Malmö
and the Medical Product Agency of Sweden. Written
informed consent was obtained from all parents and
from children if possible. The study was performed in
accordance with the Declaration of Helsinki and Good
Clinical Practice.
Subjects and study protocol
The study was a 2-year prospective, randomized, open-
label, multicentre trial in short prepubertal children with
isolated GHD or ISS [22] naïve to GH treatment. Indi-
vidual GH responsiveness was estimated by our growth
response prediction model for children with GHD and
ISS [23], and the patients were randomized in 1:2 pro-
portions to receive either a standard or an individualized
GH dose during 2 years of catch-up growth to a presetgrowth target, mid-parental height SDS (MPHSDS).
Randomization variables included gender, weightSDS at
birth, heightSDS at age 1 year, GHmaxAITT (during an ar-
ginine–insulin tolerance test), GHmax24h profile (during
24h spontaneous GH sampling), age and heightSDS at
start, the child’s heightSDS difference to its MPHSDS (diff
MPHSDS) at start, and predicted 1
st year Δ heightSDS
[23]. No patients with syndromes, chronic diseases or
complete GH insensitivity were included in the study
population.
Upon inclusion, all patients had a heightSDS below
−2.0 [24] and a growth velocity below −1.0 SDS. 128
children (38 girls, 90 boys) followed the protocol [22].
Both the results from the GHmaxAITT and the
GHmax24h profile were used to separate children with
GHD from those with ISS. Classic GHD was defined
based on a GHmax below 32 mU/L (using polyclonal
assay, WHO IRP 80–505) corresponding to 24 mU/L
(using monoclonal assay) and equivalent to the ‘old cut-
off of 10 μg/L’ [18]. According to this definition, 39 chil-
dren had isolated GHD and 89 had ISS. However, when
using GHmax results exclusively from the AITT, 90 chil-
dren were assigned the diagnosis of GHD and 38 the
diagnosis of ISS. Additionally, all of our patients fulfilled
the criteria for GHD according to a growth velocity
lesser than −1.0 SDS, IGF-I below −1 SD of sex and age
specific references, bone age retardation of more than
1,5 years [18,22].
To address the question concerning GH thresholds
and to study the possible dose-dependency, the analysis
focused on the individualized treatment group (n=87).
We used data from prepubertal children included in a
trial, randomized to individual GH doses in the range of
17–100 μg/kg/d according to their growth-related GH
responsiveness; with dose-adjustment for the estimated
difference to the preset height target (i.e. MPHSDS) at 2
years on GH in order to make it possible for each child
to reach its MPHSDS within a 2 year period. [22]. Chil-
dren with a higher predicted growth response, calculated
before start of treatment, received a lower individual GH
dose, and those with a lower predicted growth response
received a higher GH dose. The GH doses used in the
individualized-dose group were 17 μg/kg/day (n=3), 33
μg/kg/day (n=27), 40 μg/kg/day (n=10), 50 μg/kg/day
(n=26), 66 μg/kg/day (n=14), and 100 μg/kg/day (n=7):
the mean GH dose in this group was 49 μg/kg/day [22].
The fixed GH dose group was used as a control group
for estimating a metabolic effect of the dose selection
procedure in the trial by regressing the metabolic vari-
ables on the intended dose of the fixed GH dose group.
The intended dose is the GH dose that the patients
would have been given if they had been randomized to
the group treated with individualized dose. Since this
group was randomised to receive the fixed GH dose, any
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of the dose selection procedure independent of the dose
given. None of the six metabolic effects appeared to be
related to the dose selection procedure in the trial. Δ
ALP, Δ LSTSDS, Δ insulin and Δ IGF-ISDS showed no sig-
nificant effect, whereas Δ LVDd and to a lesser extend Δ
heightSDS were even somewhat negative correlated to
the intended dose of the fixed GH dose group (data not
shown).
Laboratory analyses and growth evaluation
GH and insulin-like growth factor I (IGF-I) assays were
performed at the Göteborg Pediatric Growth Research
Center (GP-GRC) laboratory (accredited number 1899).
For analyses of serum IGF-I, leptin, insulin, alkaline
phosphatase (ALP) and plasma GH, see our previous
publication [18]. IGF-I was converted to SDS [25].
Growth evaluation
Height was measured [22] and converted to SDS [24],
as previously described, with use of the childhood
component of the total reference [26].
Body composition
Body composition was measured by dual-energy X-ray
absorptiometry (DXA), using only one DPX-L scanner
(Lunar Co., Madison, WI) at each study centre. Regular
harmonization between the centres was performed fol-
lowing GCP/GMP. DXA assessment results in a three-
compartment model of the body consisting of fat mass,
lean soft tissue (LST) mass and bone mineral content
(BMC). All analyses were conducted using the extended
analysis program for total body analysis including bone
mineral density (BMD).
Echocardiography
Echocardiography was performed by four pediatric car-
diologists and one experienced sonographer. Each child
was examined longitudinally throughout the study by the
same cardiologist/ sonographer. Interventricular septum
thickness (IVSd), left ventricular diameter (LVDd) and left
ventricular posterior wall (LVPWd) thickness were mea-
sured in diastole using M-mode. Left ventricular mass
(LVM) was calculated using Devereux’s anatomically cor-
rected formula [27].
Statistics
For all analyses, the assumptions of normality were
assessed by analysis of skewness, kurtosis and frequency
histograms. A p-value of < 0.05 was considered to be
statistically significant.
Delta values (Δ-values) for the metabolic variables
were calculated in order to quantify changes at 2 year of
treatment compared with baseline. S-shaped piecewiselinear regression models were fitted with GH dose as the
predictor variable and the Δ-value of the metabolic vari-
ables as response variables. It consists of 3 pieces: a ho-
rizontal head and tail and a linear piece in the middle
and was plotted based on the GH-dose effect on the
dependent metabolic variables. Fitting this regression
comes down to fitting a bounded linear model with four
parameters; the usual slope and intercept of a linear
regression and an upper and lower bound for the fitted
model values. The GH dose effect was given by the max-
imum range of the fitted piecewise function, which is
equal to the difference between the fitted upper and
lower bound. Half of the GH dose effect on the respect-
ive variables was calculated based on the value halfway
between the lowest and highest level of the piecewise
function (50% Δ effect). The number of cases within each
dose group was taken into account by weighting. Corre-
sponding 90% confidence bands were calculated.
The fitted upper and lower bounds minus the fitted
intercept, divided by the fitted slope provide the two
breakpoints of the predictor variable separating the mid-
dle linear part from the horizontal head and tail. The ED
50% required to achieve (50% Δ effect) is located halfway
the two breakpoints of the predictor variable and a cor-
responding 90% confidence interval is computed. We
considered the ED 50% values of pairs of metabolic vari-
ables as significantly different if their ED50% values were
mutually outside each other's 90% confidence interval,
each providing a 5% significance level one-sided. This
ED 50% is halfway the two breakpoints of the predictor
variable separating the middle linear part from the hori-
zontal head and tail.
A one-way analysis of variance (ANOVA) with GH
dose as a bounded continuous predictor was performed
to test the piecewise linear GH effect. A non-parametric
comparison of group means (robust test of equality of
means – Welch test and Brown–Forsythe test) was con-
ducted when variances of dependent variables were not
equal across groups. To examine the influence from
the 17 μg/kg/day dose group consisting of only three
children, analysis were repeated with these children
excluded. No significant differences resulted compared
to the the complete study population. Only data con-
sistently significant were reported.
Statistical analyses were performed with SPSS 17.0
(SPSS Inc., Chicago, USA) and with Matlab version
7.13.0 (R2011b, The Mathworks, Natick, MA, USA).
Results
Dose-dependency
The variables were analyzed as Δ values between the
start and 2 years of GH treatment. For each of the six
dose groups, the mean Δ was calculated (Δ dose-group
mean), and is shown for the 87 children receiving
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dose–response relationships are shown in Figure 1.
When performing ANOVA and linear regression, sub-
stantial lipolytic effects were seen in all groups as
demonstrated by changes in the variables fat mass and
leptin from baseline to 2 yrs of treatment; however, no
dose–response differences were observed between the
GH dose groups for Δ fat massSDS, Δ leptin, Δ bone age,
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Figure 1 a.Dose–response relationship of outcome variables – relativ
variables fitted with S-shaped piecewise linear regression lines with corresp
the maximum range of the fitted piecewise function. The lowest level of th
diamonds indicate the percentage change (Δ) in dose-group means (betw
dose on the x-axis. LVDd: Left ventricular diameter in diastole, ALP: alkaline
The effective GH dose (ED 50%) required to achieve half of the dose effect
part of the piecewise linear GH dose effect. b.Dose–response relationship o
of metabolic outcome variables fitted with S-shaped piecewise linear regre
dots indicate the change (Δ) in response values (between start and 2 years
treatment on the y-axis vs GH dose on the x-axis. The diamonds show the
alkaline phosphatase, LST: lean soft tissue, IGF-I: insulin-like growth factor I.
effect is calculated according to the linear regression equation of the middLVM was found to be significant at the initial analysis
(ANOVA p-value = 0.013) and ED 50% of 36 μg/kg/day.
Excluding the small 17 μg/kg/day group, significance
was lost and the data is not included in Additional file 1.
Effective GH dose at ED 50%
Dose-dependent increases of the dose-group means of
Δ LVDd, Δ ALP, Δ LSTSDS, Δ insulin, Δ heightSDS and
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e changes. Dose–response relationships between metabolic outcome
onding 90% confidence intervals. The y-axis is scaled as percent (%) of
e piecewise function is set to 0% and the highest to 100%. The
een start and 2 years) of the metabolic variables on the y-axis vs GH
phosphatase, LST: lean soft tissue, IGF-I: insulin-like growth factor I.
is calculated according to the linear regression equation of the middle
f outcome variables – absolute changes. Dose–response relationship
ssion lines with corresponding 90% confidence intervals. The small
) for 87 children receiving individualized growth hormone (GH)
dose-group means. LVDd: Left ventricular diameter in diastole, ALP:
The effective GH dose (ED 50%) required to achieve half of the dose
le part of the piecewise linear GH dose effect.
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given as percentages of the maximum range, while
Figure 1b shows the same data, but now with the original
scale. The lower the ED 50%, the higher is the responsive-
ness of a given variable. The ED 50% was lowest for Δ
LVDd and highest for Δ IGF-ISDS (). The ED 50% for
Δ ALP, Δ LST, Δ insulin, and Δ heightSDS lay in the
interval between these two extremes in ascending or-
der. Differences between the Δ dose-group means for
the metabolic variables were tested for a piecewise linear
GH dose effect by one-way ANOVA with GH dose as a
bounded continuous predictor, Additional file 1.Dose-responses to GH treatment
Classic dose–response curves are depicted for the six
different GH doses in the 87 children receiving indivi-
dualized GH treatment, Figure 2.
Absolute dose-group means of LSTSDS, insulin (mU/L),
and IGF-ISDS at start of treatment were set to 0% and
compared with values from 1 and 2 years of treatment.
IGF-ISDS at start of treatment was also compared with
values at 3 months of treatment.
Low GH doses were associated with the smallest
responses. High GH doses resulted in marked responses,
with an increase in LSTSDS by more than 60% relative to
baseline and an increase of more than 250% for levels
of insulin and IGF-ISDS during the 2-year treatment
period, Figure 2.Figure 2 Examples of Dose–response relationship. Dose–response relat
receiving individualized GH treatment. The dose-group means at start of tr
with dose group mean values at 3 months, and after 1 and 2 years of treat
standard deviation score. (The absolute Δ values are presented in ref 18).Thresholds of GH dose effects
An overview of the principal relationships between GH
dose effects is shown in Figure 3. GH dose thresholds,
correspond to the ED 50%,. are depicted as a staircase
with increasing GH doses needed to achieve a certain
metabolic effect. Variables are given as Δ between start
and at 2 years of GH treatment.Discussion
In the present study, different thresholds for tissue and
metabolic responses to GH treatment were found in
short children who had varying GH secretion capacities,
as well as varying responsiveness to GH.Cardiac response to GH
Cardiac tissue, estimated by LVDd, was found to be the
most GH-sensitive of the variables evaluated (effects seen
from a dose of 33 μg/kg/d). This is in line with the fin-
dings of Capalbo et al. [28] who found that LVDd
increased during treatment with a dose of 30 μg/kg/d.
From the available data, it is difficult to draw conclusions
concerning the mechanism responsible for GH effects on
heart size. We have, however, previously shown the pres-
ence of GH receptors in cardiac tissue in children, indi-
cating that a direct effect of GH on the heart is likely
[29]. Even though GH responsiveness was high, there
were no adverse effects seen on any measurement of car-
diac function or on blood pressure during the study [30].ionship for the six different growth hormone (GH) doses in 87 children
eatment are set to 0% increase from baseline values, and compared



















































Figure 3 The threshold staircase hypothesis. The “threshold hypothesis” is presented in accordance with results from the present study as a
staircase of growth hormone (GH) dose needed for an effect (no scaling). Dose–response thresholds for metabolic markers represent different
metabolically active tissues or metabolic functions compared with the longitudinal growth response. LVDd: Left ventricular diameter in diastole,
ALP: alkaline phosphatase, LST: lean soft tissue, IGF-I: insulin-like growth factor I. Variables are given as change (Δ) between start and at 2 years of
GH treatment. The light-grey boxes mark the 90% confidence interval (CI).
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It has been shown that GH treatment at a dose of
57 μg/kg/d given to children born small for gestational
age (SGA) can lead to an increase in muscle mass,
and a concomitant decrease in fat mass [31]. However,
data showing a dose-dependency increase in LST are
lacking. We found that LST mass increased in a dose-
dependent manner for the six GH doses administered.
This effect was most marked at GH doses above 33
μg/kg/d, and the ED 50% for gain in LST mass was in
the mid-range (47 μg/kg/d). This dose is in the same
range as that found to promote longitudinal bone
growth (51 μg/kg/d), confirming our previous findings
of anabolic GH effects.
As demonstrated previously using principal compo-
nent analysis [18], a strong lipolytic effect was found for
all GH doses, seen by changes in fat mass and fat mass
index, but no GH dose–response effect was seen. A pos-
sible explanation is that in the dose range studied the
lipolytic effect had already reached its maximum, mak-
ing lipolytic variables the most sensitive to GH. Early
leptin reduction after the start of GH treatment was
found previously to be positively correlated with first
year growth response in a group of short children trea-
ted with 33 μg/kg/day; however, there was a wide range
in Δ leptin levels as for growth response; at that time noindividual responsiveness was possible to estimate [11].
It is well known that fat mass decreases in GH-deficient
adults when they are treated with GH [32]. Further stud-
ies are needed to determine the dose response for the
lipolytic effects at lower doses in children.
GH effect on alkaline phosphatase
Increased serum bone-specific ALP is known to be a
reliable and early sign of increased bone metabolism
and correlates to first year growth response in GH-
deficient children [33]. In the present study, ALP activity
was found to be more responsive than longitudinal bone
growth to a given GH dose.
GH dose-effect on insulin and insulin-sensitivity
GH doses above the common dose range of 25–35 μg/kg/
d used for GH-deficient children [34], resulted in greater
insulin increases than lower doses, although insulin levels
did not exceed the normal range. This confirms previous
studies that insulin levels are lower than normal at base-
line in GH-deficient individuals [35]. In short children
born SGA, no impaired GH dose–response effect on in-
sulin has been reported in a dose range between 33
and 66 μg/kg/d [36].
GH exerts both insulin-like and insulin-antagonistic
effects in vitro [4]. An insulin-like effect has been
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In the present study the ED 50% for the insulin enhance-
ment was 48 μg/kg/d, which is very close to the ED 50%
of 51 μg/kg/d for height gain found in the present study.
Thus, the insulin antagonist effect of GH seems to be
equally or more responsive to GH than the effect on
IGF-I. An explanation for this may be that we used SDS
for IGF-I, but not for fasting insulin, where mU/L was
used. Insulin may be required as a growth factor during
the catch-up growth phase, so the observation of a dose-
dependent increase should be viewed as more than just
compensation for GH-induced insulin resistance.
GH dose-effect on IGF
We demonstrated a marked dose–response effect on IGF-
ISDS. Thus, as for LST mass, the prediction of growth re-
sponse is not valid for IGF-ISDS levels. This is in line with
findings in groups where individual responsiveness was
not addressed, and GH therapy resulted in increasing
IGF-ISDS in a dose-dependent manner in prepubertal chil-
dren, with more dramatic changes being observed at
higher doses (50 and 100 μg/kg/day vs 25 μg/kg/d) [39],
and 100 μg/kg/d compared to 43 μg/kg/d in pubertal GH-
deficient patients [40].
In the present study, the ED 50% for IGF-ISDS was
57 μg/kg/d, which was the highest dose observed for any
metabolic variable. Therefore, liver response to IGF-I
secretion was found to have a higher threshold than both
height gain and muscle growth in the present study.
GH dose-effect on catch-up growth
In order to be able to compare metabolism and growth,
height gain was studied in the present study and not the
height target of the study, i.e. the diff MPHSDS. The
growth effect associated with individualized GH doses
was quantified and presented in Figure 1. Thus, a GH
dose of 51 (47, 56) μg/kg/d was necessary in order to
achieve half of the height gain. In previously performed
studies in children with ISS, GH had a dose-related ef-
fect on longitudinal bone growth in the dose ranges of
33–67 μg/kg/d [21] and 31–47 μg/kg/d [41]. In GH-
deficient children, an increase in GH dose from 25 to 50
μg/kg/d resulted in a sustained increase in growth vel-
ocity, whereas in this study no additional effect was
observed with a further increase in dose to 100 μg/kg/d,
the highest GH dose in the trial given only to the most
non-responsive children [39]. However, in a randomized
GH dose study during puberty in GH-deficient children,
a dose dependent effect (33 μg/kg/d vs. 67 μg/kg/d)
was found [42]. This is in line with prior evidence for a
dose-dependent effect of higher doses on adult height
in children with ISS [43]. To summarize, the adult
height achieved in GH-deficient children treated with
GH replacement therapy has been found to be dose-dependent [34,42], as has adult height in children with
ISS [21,41,43].
Effects on metabolism
There are, however, only a few studies on the metabolic
consequences of GH therapy in children. Ciresi et al.
[12] studied metabolic parameters in GH-deficient chil-
dren, but the question of dose-dependency was not
investigated. Mauras et al. [40] compared IGF-I levels in
two different GH dose groups in adolescents with GHD.
Cohen et al. [39] analyzed the response of IGF-I, IGFBP-
3, fasting glucose, fasting insulin, HbA1c and height to
three different GH doses (25, 50, and 100 μg/kg/day) in
prepubertal GH-deficient children. However, the ques-
tion of whether there were different metabolic thresholds
was neither addressed nor individual responsiveness.
In a recent report on our study group, we found dose-
dependent effects on height gain, body composition and
metabolism [18]. There are no comparable prospective
randomized studies. Nevertheless, our data can be com-
pared with reported qualitative effects in response to
different GH doses, which suggest that dose–response
effects exist [21,39].
Our study included children classified as both GHD
and ISS as our study also includes aspects on tissue
responsiveness, ranging from high to low within both
diagnostic groups. Without a wide range, it would not
have been possible to perform our study on the hypothesis
of varying thresholds for different tissues and metabolic
markers [19,20].
A fact that influences the interpretation of the results
is, that the individual GH dose in the trial was selected
based on GH responsiveness according to estimated/
expected growth response and adapted so that the child
would reach MPHSDS within 2 years, although limited by
the set maximal GH dose of 100 μg/kg/d. None of the
metabolic effects presented here was found to be related
to the dose selection procedure in the trial.
The strengths of the present study are that we were
able to compare many different effects within the same
individual, as well as assessing inter-individual variations.
When monitoring GH treatment in the clinical setting,
it is essential to know which processes will be affected
and which marker will be the first to react to treatment
based on responsiveness. The aim with estimating indi-
vidual responsiveness is to set a target for treatment ef-
fect – it may be growth response for which we now have
prediction models. In the future, prediction models may
also be constructed for the metabolic markers studied in
this paper.
Conclusions
GH dose-dependent thresholds for different metabolic
effect were found in the current study, Figure 3. Cardiac
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ment, followed by muscle tissue and height gain. Insulin
levels incresed, reflecting GH-induced resistance and in-
sulin was found to be more sensitive to GH than IGF-I,
suggesting that insulin is as a growth factor during the
catch-up growth phase in prepubertal short children.Additional file
Additional file 1: Table S1. Increase in studied variables in the different
dose groups.Abbreviations
ALP: Alkaline phosphatase; ANOVA: Analysis of variance; Apo
A-II: Apolipoprotein A-II; BMC: Bone mineral content; BMD: Bone mineral
density; Δ: Delta; ED 50%: Effective dose 50%; DBP: Diastolic blood pressure;
DXA: Dual-energy X-ray absorptiometry; DPX-L: Proper name of the Lunar
pencil beam scanner; GH: Growth hormone; GHD: Growth hormone
deficiency; GP-GRC: Göteborg Pediatric Growth Research Center;
HbA1c: Glycosylated haemoglobin; HDL: High-density lipoprotein;
HOMA: Homeostasis model assessment of insulin resistance calculated as
((fasting serum insulin* fasting plasma glucose)/22.5); IGF-I: Insulin-like
growth factor I; ISS: Idiopathic short stature; IVSd: Interventricular septal
thickness in diastole; LDL: Low-density lipoprotein; Lp(a): Lipoprotein (a);
LST: Lean soft tissue; LVDd: Left ventricular diameter in diastole; LVM: Left
ventricular mass; LVPWd: Left ventricular posterior wall in diastole;
SBP: Systolic blood pressure; SDS: Standard deviation score.
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